稀有宠物医疗参与者，具有吸引人的价值主张

1Rating (Maintain):BUYTarget price (RMB):36.16AnalystFAN JunhaoSAC No. S0570524050001SFC No. BDO986fanjunhao@htsc.com+(852) 3658 6000AnalystXIONG Chenghui, PhDSAC No. S0570522120004SFC No. BPK020xiongchenghui@htsc.com+(86) 106321 1166Key dataTarget price (RMB)36.16Closing price (RMB as of 26 May)24.98Potential upside-/+ (%)45Mkt cap (RMBmn)11,6376m avg daily val (RMBmn)181.4252wk price range (RMB)11.29-26.80BVPS (RMB)9.80ShareperformanceSource:Wind(30)(6)194468May-24Sep-24Jan-25May-25(%)Ringpu Bio-TechnologyCSI300 of This report must be read with important disclosures and analyst certifications located on the end of the report.FinancialsYE 31 DecRevenue (RMBmn)+/-%Net profit (RMBmn)+/-%EPS (diluted, RMB)ROE (%)PE (x)PB (x)EV EBITDA (x)Source:Company announcements, HuataiResearch estimates This report must be read with important disclosures and analyst certifications located on the end of the report.Source:Wind, Huatai Research Source:Wind, Huatai Research This report must be read with important disclosures and analyst certifications located on the end of the report.Full financialsBalance sheetYE 31 Dec (RMBmn)Current assetsCash & equivalentsAccount receivablesOther receivablesPrepaymentsInventoriesOther current assetsNon-current assetsLong-term investmentFixed investmentIntangible assetsOther non-curr. assetsTotal assetsCurrent liabilitiesShort-term borrowingsAccount payablesOther current liabilitiesNon-currentliabilitiesLong-term borrowingsOther non-curr. liabilitiesTotal liabilitiesMinority interestShare capitalCapital reservesRetained profitShareholders’equity attr. to parentEquity & liabilitiesCash flow statementYE 31 Dec(RMBmn)Operating cash flowNet profitDepreciation/amortizationFinancial costsInvestment lossesChg in working capitalOther operating activ’sInvesting cash flowCapexLong-term investmentOther investing activ’sFinancing cash flowShort-term borrowingsLong-term borrowingsIncrease in common stockAdditional paid-in capitalOther financing activ’sNet change in cashSource:Company announcements,HuataiResearch estimates This report must be read with important disclosures and analyst certifications located on the end of the report.DisclaimersAnalyst CertificationI/We, FAN Junhao, XIONG Chenghui, hereby certify that the views expressed in this reportaccurately reflect the personal viewsof the analyst(s) about the subject securities or issuers; and no part of the compensation of the analyst(s) was, is, or willbe,directly or indirectly, related to the inclusion of specific recommendations or views inthis report.General Disclaimers and DisclosuresThis research report has been prepared by Huatai Financial Holdings (Hong Kong) Limited (hereinafter referred to as“HFHL”).The information herein is strictly confidential to the recipient. This reportis intended for HFHL, its clients and associatedcompanies. Any other person shall not be deemed a client of the Company merely from his or her receipt of this report.This report is based on information deemed reliable and publicly available by HFHL, butHFHL and its associated company(ies)(collectively, hereinafter“Huatai”)makes no guarantee as to the accuracy or completeness of such information.The opinions, assessments and projections contained herein only reflect the views and judgments at the issuance date. Huataimay issue research reports that contain inconsistent views, assessments and projections with those set out herein at differenttimes. The prices, values and investment returns of the securities or investment instruments referred to herein may fluctuate.Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital mayoccur.Huatai makes no warrants that the information in this report be kept up to date. The information contained in this report may bemodified without notice by Huatai, and investors shall pay attention to such updates or modifications when necessary.HFHL is not a U.S. Financial Industry Regulatory Authority(“FINRA”)member firm, and HFHL research analysts are notregistered/qualified as research analysts with FINRA.While every effort has been made by Huatai to ensure the content contained herein is objective and impartial, the views,conclusions and recommendations in this report are for reference only and are not to be construed as an offer or solicitation forthe purchase or sale of any security or financial instrument and in any jurisdiction where such offer or solicitation would be illegal.Such views and recommendations are not intended to provide personal investment advice and does not take into account thespecific investment objectives, financial situation and the particular needs of any specific person. Investors should give sufficientconsideration to their own particular circumstances, and fully understand and use the contents of this report, which should not beseen as the sole factor to rely on in making investment decisions. Huatai and the report’s authors shall under no ci